EU approves Roche drug Columvi for lymphoma treatment
Roche: EU approves Columvi for lymphoma treatment
Keystone-SDA
Select your language
Generated with artificial intelligence.
Listening: EU approves Roche drug Columvi for lymphoma treatment
The European Commission has approved Roche's Columvi as the first bispecific antibody for the treatment of diffuse large B-cell lymphoma after initial therapy, the pharmaceutical giant announced on Monday.
This content was published on
2 minutes
Keystone-SDA
Italiano
it
Roche: Ue approva Columvi per trattamento linfoma
Original
The approval is based on the result of the phase III Starglo trial, during which Columvi – combined with Gemcitabine and oxaliplatin (GemOx) – demonstrated a “statistically and clinically significant improvement in survival” compared to other treatments, Roche explained.
Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) is an aggressive cancer with a high risk of progression, which means that urgent and effective treatments are needed. In primary analyses, a 41% reduction in the risk of death was found among patients treated with Columvi and GemOx.
Translated from Italian by DeepL/ts
How we work
We select the most relevant news for an international audience and use automatic translation tools such as DeepL to translate them into English. An editor then briefly reviews the translation for clarity and accuracy before publication. Providing you with automatically translated news gives us the time to write more in-depth articles. The news stories we select have been written and carefully fact-checked by an external editorial team from news agencies such as Bloomberg or Keystone.
In Switzerland more people are being referred to electrical therapies or psychedelic-assisted psychotherapy. Are there similar approaches where you live?
Is your place of origin, your Heimatort, important to you?
Every Swiss citizen has a Heimatort, a place of origin, but many have never visited theirs. What’s your relationship with your Heimatort? What does it mean to you?
Ex-sect member sentenced in Zurich for sexual abuse
This content was published on
Zurich District Court has sentenced a former member of the globally active sect "Children of God" to a partial prison sentence.
SNB chairman does not rule out slowdown in Swiss growth
This content was published on
Martin Schlegel, chairman of the Swiss National Bank (SNB), does not rule out a weakening of the Swiss economy in light of the tariff dispute.
Swiss NGOs abroad to receive 10% less federal funding
This content was published on
In 2025 and 2026, Swiss NGOs will have 10% less federal funding available for international cooperation than in the previous two-year period.
Swiss parties spent less than CHF1 million on February green vote
This content was published on
Swiss political parties spent CHF 700,000 ($840,000) on campaigns in the run-up to the overwhelmingly defeated vote on February 9, according to the Swiss Federal Audit Office.
This content was published on
Swisswool, the largest Swiss wool processor, is not accepting any wool for the first time this spring. For many sheep farmers, the only option is to get rid of the wool.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.